Manzano-Gayosso P, García-Álvarez S, Badillo-Martínez K, Gálvez-Gallo I, González-Monroy J Hernández-Hernández F, Méndez-Tovar LJ

Language: Spanish
References: 21
Page: 66-71
PDF size: 251.78 Kb.

ABSTRACT

Background: in the last two decades, a notable increase in the frequency of infection-causing yeasts in hospitalized patients has been observed, mainly because of the increase in risk factors.
Material and methods: in this study, all yeast isolates obtained from different samples of patients treated in the Internal Medicine, Intensive Care Unit, Surgery, and Gynecology services of the Dr. Darío Fernández Fierro hospital (ISSSTE), during the period from 2014 to 2022 were included. Isolates were identified by traditional phenotypic characteristics using different selective and chromogenic media and by Vitek 2^® system.
Results: of 52 401 samples processed, 1 887 (3.6%) corresponded to yeastlike fungi obtained from 1 093 patients. Of the total isolates, 83.4% were obtained from women, with a significant difference. The main genera isolated were Candida (87.3%) and Trichosporon (5.5%). Sixty-one-point five percent corresponded to Candida albicans, 10% to C. tropicalis, 9% to C. glabrata, and 5.5% to Trichosporon spp. Yeast association was observed in 3.9% of samples.
Conclusion: this study shows the importance of identifying clinically important yeasts isolated from hospitalized patients; because of in addition the usual species of the genus Candida, there are other agents to consider as emerging etiological agents, such as species of the genus Trichosporon.

REFERENCES

1. Pemán, J. y Quindós, G., “Aspectos actuales de las enfermedadesinvasoras causadas por Candida y otros hongoslevaduriformes”, Rev Iberoam Micol, 2016, 33 (3):133-139. doi: 10.1016/j.riam.2015.10.001.

2. Perlroth, J., Choi, B. y Spellberg, B., “Nosocomial fungal infections:epidemiology, diagnosis, and treatment”, Med Mycol,2007, 45 (4): 321-346. doi: 10.1080/13693780701218689.

3. Yang, S.P., Chen, Y.Y., Hsu, H.S., Wang, F.D., Chen, L.Y. yFung, C.P., “A risk factor analysis of healthcare-associatedfungal infections in an intensive care unit: a retrospectivecohort study”, bmc Infect Dis, 2013, 13: 10. doi:10.1186/1471-2334-13-10.

4. Kainz, K., Bauer, M.A., Madeo, F. y Carmona-Gutiérrez, D.,“Fungal infections in humans: the silent crisis”, MicrobCell, 2020, 7 (6): 143-145. doi: 10.15698/mic2020.06.718.Rayens, E., Norris, K.A. y Cordero, J.F., “Mortality trends

5. in risk conditions and invasive mycotic disease in theUnited States, 1999-2018”, Clin Infect Dis, 2022, 74 (2):309-318. doi: 10.1093/cid/ciab336.

6. Morgan, J., Meltzer, M.I., Plikaytis, B.D., Sofair, A.N.,Huie-White, S., Wilcox, S. et al., “Excess mortality, hospitalstay, and cost due to candidemia: a case-controlstudy using data from population-based candidemiasurveillance”, Infect Control Hosp Epidemiol, 2005, 26:540-547. doi: 10.1086/502581.

7. Bretagne, S., Renaudat, C., Desnos-Ollivier, M., Sitbon,K., Lortholaryo Dromer, F. et al., “Predisposing factorsand outcome of uncommon yeast species-related fungaemiabased on an exhaustive surveillance programme(2002-14)”, J Antimicrob Chemother, 2017, 72 (6):1784-1793. doi: 10.1093/jac/dkx045.

8. Pemán, J., Zaragoza, R. y Salavert, M., “Control y prevenciónde las infecciones nosocomiales asociadas a cuidadossanitarios causadas por especies de Candida y otraslevaduras”, Rev Esp Quimioter, 2013, 26 (4): 298-311.

9. Nucci, M., Queiroz-Telles, F., Alvarado-Matute, T., Tiraboschi,I.N., Cortés, J., Zurita, J. et al., “Epidemiologyof candidemia in Latin America: a laboratory-based survey”,plos One, 2013, 8 (3): e59373. doi: 10.1371/journal.pone.0059373.

10. Kajihara, T., Yahara, K., Nagi, M., Kitamura, N., Hirabayashi,A., Hosaka, Y. et al., “Distribution, trends, andantifungal susceptibility of Candida species causingcandidemia in Japan, 2010-2019: a retrospective observationalstudy based on national surveillance data”,Med Mycol, 2022, 60 (9): myac071. doi: 10.1093/mmy/myac071.

11. Friedman, D.Z.P. y Schwartz, I.S., “Emerging fungal infections:new patients, new patterns, and new pathogens”,J Fungi (Basilea), 2019, 5 (3): 67. doi: 10.3390/jof5030067.

12. Xiao, M., Chen, S.C., Kong, F., Fan, X., Cheng, J.W., Hou,X. et al., “Five-years China hospital invasive fungal surveillancenet (chif-net) study of invasive fungal infectionscaused by non-candidal yeasts: species distributionand azole susceptibility”, Infect Drug Resist, 2018, 11:1659-1667. doi: 10.2147/IDR.S173805.

13. Méndez-Tovar, L.J., Mejía-Mercado, J.A., Manzano-Gayosso,P., Hernández-Hernández, F., López-Martínez, R.y Silva-González, I., “Frecuencia de micosis invasivas enun hospital mexicano de alta especialidad. Experienciade 21 años”, Rev Med Inst Mex Seguro Soc, 2016, 54(5): 581-587.

14. Wang, H., Xiao, M., Chen, S.C., Kong, F., Sun, Z.Y., Liao, K. etal., “In vitro susceptibilities of yeast species to fluconazoleand voriconazole as determined by the 2010 national Chinahospital invasive fungal surveillance net (chif-net) study”,J Clin Microbiol, 2012, 50 (12): 3952-3959. doi: 10.1128/JCM.01130-12.

15. Aguilera-Martínez, V., Castillo-Pérez, A.E., Linares-Segovia,B. et al., “Aislamiento de Candida sp. en los serviciosde medicina interna y la unidad de cuidados intensivosde un hospital regional”, Med Int Méx, 2022, 38 (2): 268-274. doi.org/10.24245/mim.v38i2.4935.

16. Camacho-Cardoso, J.L., Martínez-Rivera, M.A., Manzano-Gayosso, P., Méndez-Tovar, L.J., López-Martínez, R.y Hernández-Hernández, F., “Detección molecular deespecies de Candida en especímenes de pacienteshospitalizados”, Gac Med Mex, 2017, 153: 581-589. doi:10.24875/GMM.17002535.

17. Hernández-Hernández, F., Córdova-Martínez, E. y Manzano-Gayosso, P., “Frecuencia de micosis en pacientesinmunosuprimidos de un hospital regional de la Ciudadde México”, Salud Publ Mex, 2003, 6 (45): 455-460.

18. Pote, S.T., Sonawane, M.S., Rahi, P., Shah, S.R., Shouche,Y.S., Patole, M.S. et al., “Distribution of pathogenicyeasts in different clinical samples: their identification,antifungal susceptibility pattern, and cell invasion assays”,Infect Drug Resist, 2020, 13: 1133-1145. doi:10.2147/IDR.S238002.

19. Seyoum, E., Bitew, A. y Mihret, A., “Distribution of Candidaalbicans and non-albicans Candida species isolatedin different clinical samples and their in vitro antifungalsusceptibility profile in Ethiopia”, bmc Infectious Diseases,

20. 2020, 20 (1): 231. doi: 10.1186/s12879-020-4883-5.20. Cendejas-Bueno, E., Kolecka, A., Alastruey-Izquierdo,A., Theele, B., Groenewal, M., Kostrzewa, M. et al.,“Reclassification of the Candida haemulonii complexas Candida haemulonii (C. haemulonii group i), C. duobushaemuloniisp. nov. (C. haemulonii group ii), and C.haemulonii var. vulnera var. nov.: three multiresistanthuman pathogenic yeasts”, J Clin Microbiol, 2012, 50(11): 3641-3651. doi-org.pbidi.unam.mx:2443/10.1128/JCM.02248-12.

21. Satoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y.,Uchida, K. yYamaguchi, H., “Candida auris sp. nov., anovel ascomycetous yeast isolated from the externalear canal of an inpatient in a Japanese hospital”, MicrobiolImmunol, 2009, 53 (1): 41-44. doi-org.pbidi.unam.mx:2443/10.1111/j.1348-0421.2008.00083.x.